Dabigatran.Etexilat Mesylate (872728-81-9)

  • For any enquiries about this API or any of Tofigh Daru’s other products, please contact:
  • Contact Us >>

Product Detail

Mechanism:

Dabigatran etexilate is an inactive pro-drug that is converted to dabigatran, the active form, by esterase-catalyzed hydrolysis in the plasma and liver. Dabigatran, the main active principle in plasma, is a rapid-acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, enables thrombus formation by activating factors V, VIII, and XI and catalyzing the conversion of fibrinogen to fibrin. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Unlike heparin, which can only bind free thrombin, dabigatran is capable of inhibiting free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.

Storage conditions: stor in light-resistant and well closed container. protect from moisture below 30 C.

Packaging: : polyethylene nylon plastic bag

CAS Number:  872728-81-9

Formula: C35H45N7O8S

Molecular Weight: 723.846 g/mol

Method of Analysis: In-House

Application:

Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is the first synthetic, competitive and reversible direct thrombin inhibitor orally available. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. As well as being used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, it is used in deep vein thrombosis and pulmonary embolism in persons who have been treated for 5–10 days with parenteral anticoagulant (usually low molecular weight heparin), and also to prevent deep vein thrombosis and pulmonary embolism in some circumstances.